-
Featured
Biomarkers of T Cell Exhaustion in Checkpoint Inhibitor Therapy
Could altering the balance between two CD8+ T cell states enhance immunotherapies? Research from the Massachusetts General Hospital Cancer Center seeks to find the answer.
-
Featured
New Approach to CAR T-Cell Therapy for Glioblastoma Aims to Circumvent Antigen Escape
A dual-antigen approach to immunotherapy for glioblastoma, pioneered at Massachusetts General Hospital, addresses antigenic heterogeneity and may have applications for treating other types of solid tumors.
-
Featured
Using Immunotherapy to Treat Brain Tumors
In this video, William Curry, MD, discusses advancements in immunotherapy to target brain tumors. In clinical trials, he has seen the safety and strong immune activity of vaccinating patients with their own tumor cells, which has made him optimistic about the future of treatment for patients with brain tumors.
Immuno-Oncology contributors
-
Bob S. Carter, MD, PhD
Chief, Neurosurgery Service
Recent Article
Patient-derived Dopamine Neurons Show Promise in Parkinson's Treatment
-
Chin-Lee Wu, MD, PhD
Associate Pathologist, Massachusetts General Hospital and Mass General Cancer Center, Associate Professor of Pathology, Harvard Medical School, Director, Genitourinary Pathology Services
Recent Article
Review: Renal Cell Carcinomas Associated with Microphthalmia Transcription Factors -
Joseph H. Schwab, MD
Chief, Orthopaedic Spine Surgery, Director, Spine Oncology & Co-Director, Stephen L. Harris Chordoma Center, Associate Professor of Orthopedic Surgery, Harvard Medical School
Recent Article
Minor Complications Associated with Increased Mortality Risk After Surgery for Metastases in Long Bones
-
Kerry L. Reynolds, MD
Clinical Director, Inpatient Oncology Units, Director, Severe Immunotherapy Complications Program
Recent Article
Researchers Chart the Course of Severe Checkpoint Inhibitor-related Colitis -
Michael L. Dougan, MD, PhD
Physician, Division of Gastroenterology, Massachusetts General Hospital, Director, Mass General GI Center for Cancer Complications
Recent Article
Subset of Cancer Patients with Checkpoint Inhibitor–Associated Enterocolitis Respond to Budesonide -
Nir Hacohen, PhD
Director, MGH Center for Cancer Immunology
Center for Cancer Research , Professor of Medicine, Harvard Medical School, Senior Member, Broad InstituteRecent Article
Biomarkers of T Cell Exhaustion in Checkpoint Inhibitor Therapy
-
Tomas G. Neilan, MD, MPH
Director, Cardio-Oncology Program, Co-Director, Cardiac MR PET CT Program
Recent Article
Cardiac Injury and Cardiovascular Events Are Common After CAR T Therapy
-
Whitfield B. Growdon, MD
Center for Gynecologic Oncology
Recent Article
Developing Precision Therapies for Ovarian Cancer
-
William T. Curry, MD
Co-Director, Mass General Neuroscience , Director of Neurosurgical Oncology
Recent Article
Endonasal Surgery Using High-Speed Drill Puts Health Care Team at Risk of COVID-19
Mass General Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.
